Trastuzumab was the most frequently used targeted therapy in patients with stage I–III HER2+ BC (n = 3570, 78.7%), and endocrine treatment was received by 2270 (50.1%) (Table 2). The gene discussed is ERBB2; the disease is breast cancer.